Transcode Therapeutics
NASDAQ: RNAZBoston, US · Delaware corporation
TransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
BiotechHealthtech
Founders & leadership
TA
Thomas A. FitzgeraldExecutive
Board
MM
Magda MarquetBoard director
EM
Erik MantingBoard director
PC
Philippe CalaisBoard director
Competitors · 2
by search overlapBioworld122 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Day One Biopharmaceuticals81 shared keywordsDay One Biopharmaceuticals is an oncology drug developer that pursues a "search and development" strategy to bring targeted cancer medicines to patients of all ages, with a focus on pediatric low-grade glioma (pLGG). The company is part of Servier.
Companies competing with Transcode Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$8M disclosed across 1 round · 2024
▶$8MraisedDec 2024 · 6 investors · BiotechnologyRule 506(b)
▶$8MraisedDec 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Magda MarquetDirector
- Erik MantingDirector
- Thomas A. FitzgeraldExecutive Officer, Director
- Philippe CalaisDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $320K
- Placement agents
- The Benchmark Company LLC, A.G.P./Alliance Global Partners
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Transcode Therapeutics do?
- TransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
- How much funding has Transcode Therapeutics raised?
- Transcode Therapeutics has disclosed $8M raised across 1 round.
- Where is Transcode Therapeutics headquartered?
- Transcode Therapeutics is headquartered in Boston, US.